Market Research Industry Reports

Hepatitis C: Competitive Landscape to 2026

  • DESCRIPTION
  • TABLE OF CONTENTS
  • RELATED REPORTS
  • SAMPLE REQUEST
  • REVIEWS
Hepatitis C: Competitive Landscape to 2026

Summary

Hepatitis C is a liver infection caused by the hepatitis C virus (HCV), a small enveloped RNA virus. If left untreated, chronic infection can result in fibrosis, cirrhosis, hepatocellular carcinoma, and eventually death. HCV is spread primarily by exposure to infected blood.

This report provides an assessment of the pipeline, clinical, and commercial landscape of hepatitis C. Overall, GlobalData expects next-generation direc-acting antiviral (DAA) regimens to drive growth, with opportunities for new entrants residing primarily in emerging markets (Brazil and China) over the next decade (2016-2026).

Scope

This report combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace. Components of the slide deck include -
- Pipeline Assessment: regional breakdown, promising late-stage products, early-stage pipeline by molecule type
- Clinical Trials Assessment: trial breakdown by phase, leading industry and non-industry sponsors, enrollment analytics
- Commercial Assessment: leading marketed products, current and future players
- Competitive Landscape Analysis: key market events (2016-2026).

Reasons to buy

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global hepatitis C market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global hepatitis C market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

1. Preface 2
1.
1.2 Abbreviations 3
1.3 Related Reports 4
1.4 Upcoming Related Reports 5
2. Executive Summary 6
2.1 Key Findings 7
2.2 Key Events 8
3. Introduction 9
3.1 Report Scope 10
3.2 Disease Overview and Epidemiology 12
4. Pipeline Assessment 16
4.1 Pipeline Overview 17
4.2 Pipeline Breakdown by Region/Country 19
4.3 Pipeline Breakdown by Molecule Type and Target 20
4.4 Drug Review Designations 21
4.5 Products in Clinical Development 22
5. Clinical Trial Assessment 24
5.1 Clinical Trials Overview 25
5.2 Top Sponsors of Clinical Trials in MRSA 26
5.3 Trial Breakdown by Region 28
5.4 Therapy Area Perspective 29
5.5 Enrollment Analytics 30
6 Commercial Assessment 33
6.1 Leading Marketed Products 34
6.2 Current & Future Players 35
7. Competitive Landscape Analysis (2016-2026) 36
7.1 Events Classification Overview 37
7.2 7MM 38
7.3 Emerging Markets (Brazil and China) 39
8 Appendix 40
8.1 Sources 41
8.2 Methodology 42
8.3 Key Events Included in the Analysis 43
8.4 About the Authors 44
8.5 About GlobalData 47
8.6 Disclaimer 49

Hepatitis C Virus Envelope Protein E2 - Pipeline Review, H2 2018

Hepatitis C Virus Envelope Protein E2 - Pipeline Review, H2 2018According to the recently published report Hepatitis C Virus Envelope Protein E2 - Pipeline Review, H2 2018; Hepatitis C Virus

USD 3500View Report

2018 US Hepatitis Diagnostic Testing Market: Supplier Shares, Volume and Sales Segment Forecasts for 10 Assays, Competitive Analysis, Emerging Technologies, Instrumentation Review, Opportunities for Suppliers

Complete report $3,900.  DataPack (test volumes, sales forecasts, supplier shares) $2,500.The report presents a detailed analysis of the Hepatitis diagnostics market in the US. Current scientific views on the Hepatitis

USD 2450View Report

Hepatitis C: KOL Insight

DescriptionIntroductionAs hepatitis C cures multiply, how do experts evaluate the optionsSince the launch of Sovaldi (sofosbuvir; Gilead) in 2013, the hepatitis C (HCV) landscape has developed at a rapid pace.

USD 395View Report

Your are not allow to send sample request
Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 3495
  • Site Licence    USD 6990
  • Enterprise Wide Licence    USD 10485
$ 3495

Reports Details

Published Date : Jun 2018
No. of Pages :49
Country :Global
Category :Pharmaceuticals and Healthcare
Publisher :GlobalData
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube